Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GMTX Stock Alerts

Gemini Therapeutics (GMTX) Financials

Gemini Therapeutics logo
$80.05 +1.38 (+1.75%)
As of 09/2/2026
Compare
Annual Income Statements for Gemini Therapeutics

Annual Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -36 -47 -76 -109 -212
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109 -212
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109 -212
Total Pre-Tax Income 		-41 -36 -47 -76 -109 -212
Total Operating Income		 -34 -31 -47 -91 -130 -236
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 31 47 91 130 236
Selling, General & Admin Expense		 5.87 5.76 14 22 33 65
Research & Development Expense		 28 25 33 69 97 171
Total Other Income / (Expense), net		 -6.80 -5.04 0.65 15 21 24
Interest Expense		 6.83 - - 0.00 0.57 3.61
Interest & Investment Income		 0.04 0.01 0.71 15 21 28
Other Income / (Expense), net		 -0.01 -5.05 -0.06 -0.00 -0.00 0.05
Income Tax Expense		 - - 0.00 0.10 0.36 0.36
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - 0.00 -0.32 -0.68
Basic Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96) ($6.01)
Weighted Average Basic Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M 35.30M
Diluted Earnings per Share		 ($2.70) ($40.95) ($45.05) ($3.42) ($3.96) ($6.01)
Weighted Average Diluted Shares Outstanding		 15.12M 878.41K 1.04M 22.32M 27.61M 35.30M
Weighted Average Basic & Diluted Shares Outstanding		 15.12M 40.36M 19.00M 24.68M 34.57M 38.16M

Quarterly Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -24 0.00 -26 -27 -29 -34 -55 -62 -94 -65 -61
Consolidated Net Income / (Loss)		 -24 -27 -26 -27 -29 -34 -55 -62 -61 -64 -60
Net Income / (Loss) Continuing Operations		 -24 -27 -26 -27 -29 -34 -55 -62 -61 -64 -60
Total Pre-Tax Income 		-24 -27 -26 -26 -29 -34 -55 -62 -60 -63 -59
Total Operating Income		 -30 -31 -31 -33 -35 -40 -61 -68 -67 -70 -65
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 30 31 31 33 35 40 61 68 67 70 65
Selling, General & Admin Expense		 7.15 7.76 7.37 8.17 9.75 12 15 17 21 24 18
Research & Development Expense		 23 24 23 25 25 28 46 50 46 46 47
Total Other Income / (Expense), net		 6.17 4.52 4.56 6.37 5.27 5.98 6.22 5.48 6.53 6.07 5.61
Interest Expense		 - - 0.00 0.00 - 0.90 0.91 0.92 0.88 0.84 0.91
Interest & Investment Income		 4.68 4.52 4.57 6.36 5.84 6.88 7.06 6.41 7.41 6.89 6.53
Other Income / (Expense), net		 1.49 -0.00 -0.01 0.01 - -0.00 0.07 -0.02 -0.00 0.02 -0.01
Income Tax Expense		 0.03 0.01 0.06 0.11 0.18 0.12 0.05 0.10 0.09 0.05 0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.00 - - - -0.23 0.25 - - 1.53 1.04
Basic Earnings per Share		 ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64) ($1.65) ($1.54)
Weighted Average Basic Shares Outstanding		 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M 38.49M 38.69M
Diluted Earnings per Share		 ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64) ($1.65) ($1.54)
Weighted Average Diluted Shares Outstanding		 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M 38.49M 38.69M
Weighted Average Basic & Diluted Shares Outstanding		 24.68M 24.72M 29.73M 29.76M 34.57M 34.63M 34.77M 37.75M 38.16M 38.20M 38.39M

Annual Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.45 62 107 166 -168 -101
Net Cash From Operating Activities		 -33 -28 -42 -73 -94 -180
Net Cash From Continuing Operating Activities		 -34 -28 -42 -73 -94 -180
Net Income / (Loss) Continuing Operations		 -41 -36 -47 -76 -109 -212
Consolidated Net Income / (Loss)		 -41 -36 -47 -76 -109 -212
Depreciation Expense		 0.32 0.03 0.09 0.10 0.16 0.28
Amortization Expense		 - - - 0.00 -5.30 -8.52
Non-Cash Adjustments To Reconcile Net Income		 7.47 6.98 2.04 5.94 22 41
Changes in Operating Assets and Liabilities, net		 -0.73 1.43 2.44 -3.07 -1.43 -0.97
Net Cash From Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292 -394
Net Cash From Continuing Investing Activities		 -0.02 -0.07 -0.15 -0.09 -292 -394
Purchase of Property, Plant & Equipment		 -0.02 -0.07 -0.15 -0.09 -0.51 -0.93
Purchase of Investments		 - - - 0.00 -387 -850
Sale and/or Maturity of Investments		 - - - 0.00 95 456
Net Cash From Financing Activities		 34 90 149 239 218 473
Net Cash From Continuing Financing Activities		 34 90 149 239 218 473
Repayment of Debt		 0.00 0.00 0.00 0.00 -1.39 0.00
Issuance of Debt		 14 0.00 0.00 0.00 29 0.00
Issuance of Common Equity		 20 0.00 54 199 188 451
Other Financing Activities, net		 0.16 0.07 95 40 2.98 23
Cash Interest Paid		 0.35 0.00 0.00 0.00 0.20 2.80

Quarterly Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -10 -18 -62 -88 -0.20 -70 4.66 13 -50 -2.23 9.76
Net Cash From Operating Activities		 -18 -34 -15 -17 -28 -41 -48 -48 -43 -62 -44
Net Cash From Continuing Operating Activities		 -18 -34 -15 -17 -28 -41 -48 -48 -43 -62 -44
Net Income / (Loss) Continuing Operations		 -24 -27 -26 -27 -29 -34 -55 -62 -61 -64 -60
Consolidated Net Income / (Loss)		 -24 -27 -26 -27 -29 -34 -55 -62 -61 -64 -60
Depreciation Expense		 0.03 0.03 0.11 0.01 0.01 0.02 0.09 0.09 0.09 0.09 0.09
Amortization Expense		 - 0.00 - -2.50 -2.21 -2.53 -2.62 -1.74 -1.63 -1.07 -0.49
Non-Cash Adjustments To Reconcile Net Income		 0.61 7.89 12 10 -4.72 6.98 9.70 9.93 14 13 17
Changes in Operating Assets and Liabilities, net		 5.15 -15 -0.97 1.54 8.80 -12 0.17 6.24 4.81 -11 -0.93
Net Cash From Investing Activities		 -0.00 -0.07 -220 -71 -1.43 -273 52 50 -223 58 22
Net Cash From Continuing Investing Activities		 -0.00 -0.07 -220 -71 -1.43 -273 52 50 -223 58 22
Purchase of Investments		 - 0.00 - -94 -73 -347 -59 -85 -358 -94 -93
Sale and/or Maturity of Investments		 - 0.00 - - 72 75 110 135 135 152 114
Net Cash From Financing Activities		 7.76 16 173 0.43 29 244 0.89 12 217 1.70 32
Net Cash From Continuing Financing Activities		 7.76 16 173 0.43 29 244 0.89 12 217 1.70 32
Other Financing Activities, net		 38 0.81 0.57 0.40 1.20 9.96 0.89 1.53 10 1.01 2.36
Cash Interest Paid		 - 0.00 - - - 0.70 0.71 0.71 0.68 0.64 0.65

Annual Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.32 92 200 368 497 807
Total Current Assets		 5.07 90 198 366 494 804
Cash & Equivalents		 4.50 88 195 360 192 91
Short-Term Investments		 - - - 0.00 297 700
Prepaid Expenses		 0.56 2.45 3.88 5.28 3.73 13
Plant, Property, & Equipment, net		 0.29 0.11 0.17 0.17 0.75 1.16
Total Noncurrent Assets		 2.96 1.82 1.55 2.16 2.41 1.82
Other Noncurrent Operating Assets		 2.96 1.82 1.55 2.16 2.41 1.82
Total Liabilities & Shareholders' Equity		 8.32 92 200 368 497 807
Total Liabilities		 30 15 24 23 53 67
Total Current Liabilities		 25 13 23 21 23 37
Accounts Payable		 2.38 2.56 16 13 7.95 9.02
Accrued Expenses		 5.81 4.10 6.11 8.15 15 27
Other Current Liabilities		 - 6.77 0.31 0.67 0.13 0.61
Total Noncurrent Liabilities		 5.30 1.33 1.03 1.44 30 30
Long-Term Debt		 4.95 - - 0.00 28 29
Other Noncurrent Operating Liabilities		 0.35 1.33 1.03 1.44 1.55 1.25
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 78 177 345 444 740
Total Preferred & Common Equity		 -22 -64 177 345 444 740
Preferred Stock		 0.00 142 - 0.00 0.00 0.00
Total Common Equity		 -22 -64 177 345 444 740
Common Stock		 91 1.19 289 534 741 1,249
Retained Earnings		 -113 -65 -112 -189 -298 -510
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.29 0.97

Quarterly Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 244 384 376 354 510 495 709 665 630 750 735
Total Current Assets		 242 382 374 352 508 493 706 662 627 747 733
Cash & Equivalents		 236 378 371 343 281 193 123 127 141 89 99
Short-Term Investments		 - - - - 220 295 572 523 475 641 619
Prepaid Expenses		 5.72 4.13 3.72 9.33 7.30 5.79 11 12 11 17 15
Plant, Property, & Equipment, net		 0.18 0.16 0.18 0.21 0.10 0.08 1.37 1.29 1.23 1.07 0.98
Total Noncurrent Assets		 1.46 2.28 2.05 2.02 1.88 1.91 2.30 2.18 2.06 1.69 1.33
Other Noncurrent Operating Assets		 1.46 2.28 2.05 2.02 1.88 1.91 2.30 2.18 2.06 1.69 1.33
Total Liabilities & Shareholders' Equity		 244 384 376 354 510 495 709 665 630 750 735
Total Liabilities		 11 13 18 16 21 27 49 51 57 62 91
Total Current Liabilities		 9.98 9.68 14 15 20 25 19 21 27 31 30
Accounts Payable		 5.64 5.21 8.50 5.27 4.75 3.55 6.70 6.35 7.27 12 6.84
Accrued Expenses		 4.03 4.15 5.57 8.82 15 22 12 14 19 19 23
Other Current Liabilities		 0.31 0.32 0.35 0.77 0.76 0.08 0.48 0.63 0.66 0.42 0.32
Total Noncurrent Liabilities		 0.95 3.27 3.11 1.26 1.08 1.71 30 30 30 31 61
Long-Term Debt		 - - - - - - 29 29 29 29 59
Other Noncurrent Operating Liabilities		 0.95 3.27 3.11 1.26 1.08 1.71 1.63 1.55 1.37 1.28 1.21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 233 371 359 338 489 468 660 614 573 688 644
Total Preferred & Common Equity		 233 371 359 338 489 468 660 614 573 688 644
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 233 371 359 338 489 468 660 614 573 688 644
Common Stock		 368 522 524 554 731 736 992 1,001 1,022 1,263 1,279
Retained Earnings		 -135 -151 -165 -216 -242 -269 -332 -387 -450 -574 -633
Accumulated Other Comprehensive Income / (Loss)		 - - - - -0.06 0.74 0.54 0.27 0.72 -0.57 -1.61

Annual Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -6.60% -31.98% -91.85% -48.16% -81.07%
EBIT Growth		 0.00% -5.68% -32.11% -91.70% -42.35% -81.91%
NOPAT Growth		 0.00% 9.13% -53.48% -91.94% -42.35% -81.95%
Net Income Growth		 0.00% 11.92% -30.19% -63.22% -43.08% -94.03%
EPS Growth		 0.00% 11.92% -10.01% 92.41% -15.79% -51.77%
Operating Cash Flow Growth		 0.00% 15.82% -53.45% -73.87% -27.86% -92.06%
Free Cash Flow Firm Growth		 0.00% 0.00% -60.09% -159.87% -32.40% -82.78%
Invested Capital Growth		 0.00% -119.79% -73.47% 15.27% -17.76% -23.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 40.87% -129.18% -22.29% -9.45% -14.92%
EBIT Q/Q Growth		 0.00% 41.08% -130.60% -22.26% -5.12% -15.90%
NOPAT Q/Q Growth		 0.00% 49.34% -291.48% -19.22% -3.87% -15.92%
Net Income Q/Q Growth		 0.00% 47.38% -167.49% -19.25% -5.68% -17.16%
EPS Q/Q Growth		 0.00% 47.38% -147.12% -29.55% -14.45% -21.41%
Operating Cash Flow Q/Q Growth		 0.00% 50.73% -222.81% -12.45% -11.62% -9.55%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -84.47% -70.15% -10.69% -8.55%
Invested Capital Q/Q Growth		 0.00% -305.43% -736.43% -31.94% 7.38% -63.22%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.13% 100.33% 100.17%
Interest Burden Percent		 119.94% 99.96% 98.51% 83.76% 84.03% 89.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 186.80% -128.94% -36.84% -29.30% -27.73% -35.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 186.80% 198.90% -16.28% -29.30% -27.73% -35.86%
Return on Equity Simple (ROE_SIMPLE)		 186.80% 56.02% -26.52% -22.15% -24.65% 0.00%
Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91 -165
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 99.25% -40.38% -9.62% -4.56% -4.51% -7.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -18.48% -19.24% -21.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -34 -36 -48 -91 -130 -236
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -36 -47 -91 -135 -244
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.16 4.04 4.25 4.05
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.16 4.04 4.25 4.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.99 0.00 0.00 0.00 0.06 0.04
Long-Term Debt to Equity		 -0.23 0.00 0.00 0.00 0.06 0.04
Financial Leverage		 -0.78 -1.27 -1.11 -1.06 -1.04 -1.03
Leverage Ratio		 -0.38 1.81 1.15 1.09 1.10 1.10
Compound Leverage Factor		 -0.46 1.80 1.13 0.91 0.92 0.99
Debt to Total Capital		 -9,791.86% 0.00% 0.00% 0.00% 6.00% 3.79%
Short-Term Debt to Total Capital		 -7,551.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -2,240.27% 0.00% 0.00% 0.00% 6.00% 3.79%
Preferred Equity to Total Capital		 0.00% 182.68% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 9,891.86% -82.68% 100.00% 100.00% 94.00% 96.21%
Debt to EBITDA		 -0.64 0.00 0.00 0.00 -0.21 -0.12
Net Debt to EBITDA		 -0.51 0.00 0.00 0.00 3.42 3.12
Long-Term Debt to EBITDA		 -0.15 0.00 0.00 0.00 -0.21 -0.12
Debt to NOPAT		 -0.91 0.00 0.00 0.00 -0.31 -0.18
Net Debt to NOPAT		 -0.72 0.00 0.00 0.00 5.08 4.61
Long-Term Debt to NOPAT		 -0.21 0.00 0.00 0.00 -0.31 -0.18
Altman Z-Score		 -31.95 3.83 0.22 36.16 20.72 26.12
Noncontrolling Interest Sharing Ratio		 0.00% 254.26% 55.79% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.20 6.74 8.79 17.06 21.17 21.94
Quick Ratio		 0.18 6.56 8.62 16.81 21.01 21.59
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -16 -26 -67 -88 -161
Operating Cash Flow to CapEx		 -148,672.73% -40,491.18% -27,981.46% -82,541.57% -18,599.21% -19,334.73%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -154.01 -44.64
Operating Cash Flow to Interest Expense		 -4.79 0.00 0.00 0.00 -164.21 -50.01
Operating Cash Flow Less CapEx to Interest Expense		 -4.79 0.00 0.00 0.00 -165.09 -50.27
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -4.72 -10 -18 -15 -18 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.66 -7.63 2.75 -2.71 -4.20
Enterprise Value (EV)		 188 179 -166 1,034 1,425 2,236
Market Capitalization		 171 125 29 1,394 1,887 2,998
Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91 $19.60
Tangible Book Value per Share		 ($1.41) ($1.49) $4.08 $14.30 $14.91 $19.60
Total Capital		 -0.22 78 177 345 472 769
Total Debt		 22 0.00 0.00 0.00 28 29
Total Long-Term Debt		 4.95 0.00 0.00 0.00 28 29
Net Debt		 17 -88 -195 -360 -462 -762
Capital Expenditures (CapEx)		 0.02 0.07 0.15 0.09 0.51 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.63 -11 -19 -16 -20 -24
Debt-free Net Working Capital (DFNWC)		 -3.12 77 176 344 470 767
Net Working Capital (NWC)		 -20 77 176 344 470 767
Net Nonoperating Expense (NNE)		 17 14 14 13 19 47
Net Nonoperating Obligations (NNO)		 17 -88 -195 -360 -462 -762
Total Depreciation and Amortization (D&A)		 0.32 0.03 0.09 0.10 -5.15 -8.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96) ($6.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M 35.30M
Adjusted Diluted Earnings per Share		 $0.00 ($53.40) ($45.05) ($3.42) ($3.96) ($6.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.44M 1.04M 22.32M 27.61M 35.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($53.40) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.35M 19.00M 24.68M 34.57M 38.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -22 -33 -64 -91 -165
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4.99 0.00 0.00 0.00 -226.78 -65.42
NOPAT to Interest Expense		 -3.49 0.00 0.00 0.00 -158.75 -45.80
EBIT Less CapEx to Interest Expense		 -4.99 0.00 0.00 0.00 -227.67 -65.68
NOPAT Less CapEx to Interest Expense		 -3.49 0.00 0.00 0.00 -159.63 -46.06
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 38,160,065.00 38,199,089.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 38,160,065.00 38,199,089.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.70 -1.59
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -142.95% -25.25% -63.52% -86.74% -30.33% -35.05% -103.75% -96.33% -86.44% -66.01% -2.52%
EBIT Growth		 -142.64% -25.23% -63.89% -73.38% -22.41% -26.97% -98.74% -106.15% -93.86% -73.98% -6.11%
NOPAT Growth		 -97.82% -25.22% -78.05% -73.31% -16.28% -26.97% -99.05% -106.04% -93.84% -74.05% -5.97%
Net Income Growth		 -109.70% -18.30% -65.25% -88.35% -24.93% -26.48% -109.65% -134.30% -105.49% -86.31% -7.76%
EPS Growth		 90.20% 9.17% -39.19% -53.45% -0.94% 6.42% -53.40% -98.88% 19.21% -61.76% 2.53%
Operating Cash Flow Growth		 -84.13% 5.26% -20.98% -132.22% -54.94% -23.15% -211.30% -175.32% -57.04% -50.42% 7.76%
Free Cash Flow Firm Growth		 -715.80% -19.33% -245.19% -1,446.16% 8.81% -27.03% -202.79% -250.91% -98.77% -57.37% 20.09%
Invested Capital Growth		 15.27% -27.39% -89.82% -67.74% -17.76% -27.00% 41.64% 30.01% -23.34% -114.24% -101.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -49.04% -11.48% 2.17% -14.88% -4.02% -15.52% -50.46% -8.59% 1.23% -2.87% 7.09%
EBIT Q/Q Growth		 -48.98% -11.48% 1.90% -6.42% -5.18% -15.63% -53.55% -10.39% 1.10% -3.78% 6.35%
NOPAT Q/Q Growth		 -56.74% -5.88% 1.94% -6.50% -5.16% -15.62% -53.73% -10.24% 1.07% -3.81% 6.40%
Net Income Q/Q Growth		 -66.97% -14.29% 2.22% -0.94% -10.74% -15.71% -62.09% -12.80% 2.87% -4.91% 6.25%
EPS Q/Q Growth		 -82.76% -2.83% 5.50% 13.59% -20.22% 4.67% -54.90% -12.03% 7.34% -0.61% 6.67%
Operating Cash Flow Q/Q Growth		 -138.04% -88.80% 54.19% -12.79% -58.82% -50.06% -15.81% 0.25% 9.41% -43.73% 28.98%
Free Cash Flow Firm Q/Q Growth		 -2,190.71% 10.63% 24.63% 4.41% -41.62% -24.50% -79.66% -10.78% 19.78% 1.43% 8.78%
Invested Capital Q/Q Growth		 -31.94% 70.22% -166.64% -60.14% 7.38% 67.89% -22.53% -92.07% -63.22% 44.22% -15.19%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.14% 100.02% 100.23% 100.43% 100.60% 100.35% 100.09% 100.16% 100.15% 100.08% 100.12%
Interest Burden Percent		 83.43% 85.64% 85.18% 80.63% 84.75% 85.02% 89.98% 91.89% 90.25% 91.30% 91.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.30% -28.23% -21.16% -25.03% -27.73% -23.34% -26.36% -34.78% -35.86% -35.83% -39.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.30% -28.23% -21.16% -25.03% -27.73% -23.34% -26.36% -34.78% -35.86% -35.83% -39.08%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -23.84% -18.62% -22.11% 0.00% -17.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -22 -22 -23 -24 -28 -43 -47 -47 -49 -46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.00% -1.70% -1.08% -0.84% -1.28% -1.21% -2.19% -2.78% -2.23% -2.17% -2.18%
Return On Investment Capital (ROIC_SIMPLE)		 -6.03% - - - -5.12% -4.06% -6.69% -7.87% -6.10% -6.78% -6.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -28 -31 -31 -33 -35 -40 -61 -68 -67 -70 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -31 -31 -35 -37 -42 -64 -69 -69 -70 -65
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.04 4.55 2.28 3.12 4.25 2.60 2.99 4.01 4.05 3.54 4.34
Price to Tangible Book Value (P/TBV)		 4.04 4.55 2.28 3.12 4.25 2.60 2.99 4.01 4.05 3.54 4.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.06 0.04 0.05 0.05 0.04 0.04 0.09
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.06 0.04 0.05 0.05 0.04 0.04 0.09
Financial Leverage		 -1.06 -1.01 -1.02 -1.04 -1.04 -1.01 -1.02 -1.03 -1.03 -1.01 -1.02
Leverage Ratio		 1.09 1.05 1.04 1.05 1.10 1.07 1.07 1.08 1.10 1.08 1.11
Compound Leverage Factor		 0.91 0.90 0.89 0.85 0.93 0.91 0.96 0.99 0.99 0.99 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 6.00% 4.14% 4.47% 4.81% 3.79% 4.09% 8.43%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 6.00% 4.14% 4.47% 4.81% 3.79% 4.09% 8.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 94.00% 95.86% 95.53% 95.19% 96.21% 95.91% 91.57%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.21 -0.20 -0.16 -0.14 -0.12 -0.11 -0.22
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 3.42 4.57 3.48 2.76 3.12 2.57 2.40
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.21 -0.20 -0.16 -0.14 -0.12 -0.11 -0.22
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.31 -0.29 -0.24 -0.20 -0.18 -0.16 -0.31
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 5.08 6.89 5.26 4.12 4.61 3.77 3.49
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.31 -0.29 -0.24 -0.20 -0.18 -0.16 -0.31
Altman Z-Score		 36.72 57.22 31.54 32.39 21.35 21.37 21.66 23.94 26.81 23.46 18.09
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.06 23.70 25.02 19.36 21.17 37.65 32.11 23.45 21.94 24.00 24.14
Quick Ratio		 16.81 23.07 24.66 19.13 21.01 37.07 31.54 23.03 21.59 23.45 23.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -21 -16 -15 -21 -27 -48 -53 -43 -42 -38
Operating Cash Flow to CapEx		 -593,200.00% -50,147.76% 0.00% 0.00% -6,140.98% -4,862.04% -133,105.56% -183,842.31% -216,500.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -29.81 -52.78 -58.03 -48.34 -49.85 -42.27
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -46.13 -52.66 -52.13 -49.04 -73.74 -48.68
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -47.08 -52.70 -52.15 -49.06 -73.74 -48.68
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -15 -4.54 -12 -19 -18 -5.77 -7.07 -14 -22 -12 -14
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.75 -0.98 -5.73 -7.84 -2.71 -1.23 5.05 5.82 -4.20 -6.59 -7.17
Enterprise Value (EV)		 1,034 1,194 613 973 1,425 1,050 1,213 1,710 2,236 1,739 2,135
Market Capitalization		 1,394 1,537 1,114 1,461 1,887 1,716 1,834 2,297 2,998 2,440 2,794
Book Value per Share		 $14.30 $13.70 $19.77 $15.74 $14.91 $19.10 $17.73 $16.49 $19.60 $18.04 $16.86
Tangible Book Value per Share		 $14.30 $13.70 $19.77 $15.74 $14.91 $19.10 $17.73 $16.49 $19.60 $18.04 $16.86
Total Capital		 345 338 489 468 472 689 643 602 769 718 704
Total Debt		 0.00 0.00 0.00 0.00 28 29 29 29 29 29 59
Total Long-Term Debt		 0.00 0.00 0.00 0.00 28 29 29 29 29 29 59
Net Debt		 -360 -343 -501 -487 -462 -666 -621 -587 -762 -701 -658
Capital Expenditures (CapEx)		 0.00 0.07 -0.00 -0.01 0.45 0.85 0.04 0.03 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -5.52 -13 -20 -20 -7.80 -8.99 -15 -24 -14 -15
Debt-free Net Working Capital (DFNWC)		 344 337 488 468 470 687 641 600 767 716 702
Net Working Capital (NWC)		 344 337 488 468 470 687 641 600 767 716 702
Net Nonoperating Expense (NNE)		 2.78 4.93 4.76 3.60 5.27 6.12 12 15 14 15 14
Net Nonoperating Obligations (NNO)		 -360 -343 -501 -487 -462 -666 -621 -587 -762 -701 -658
Total Depreciation and Amortization (D&A)		 0.03 0.03 0.11 -2.49 -2.20 -2.51 -2.54 -1.65 -1.54 -0.98 -0.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64) ($1.65) ($1.54)
Adjusted Weighted Average Basic Shares Outstanding		 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M 38.49M 38.69M
Adjusted Diluted Earnings per Share		 ($1.06) ($1.09) ($1.03) ($0.89) ($1.07) ($1.02) ($1.58) ($1.77) ($1.64) ($1.65) ($1.54)
Adjusted Weighted Average Diluted Shares Outstanding		 22.32M 24.81M 25.65M 29.94M 27.61M 33.32M 35.02M 35.18M 35.30M 38.49M 38.69M
Adjusted Basic & Diluted Earnings per Share		 ($1.06) $0.00 $0.00 $0.00 ($1.07) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.68M 24.72M 29.73M 29.76M 34.57M 34.63M 34.77M 37.75M 38.16M 38.20M 38.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -22 -22 -23 -24 -28 -43 -47 -47 -49 -46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -44.54 -67.41 -73.84 -75.85 -82.35 -71.68
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -31.17 -47.24 -51.68 -53.09 -57.66 -50.17
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -45.48 -67.45 -73.87 -75.87 -82.35 -71.68
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -32.12 -47.28 -51.70 -53.11 -57.66 -50.17
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Data integrity note: The supplied statements identify the company as Disc Medicine, Inc. (NASDAQ:IRON), not Gemini Therapeutics (NASDAQ:GMTX). The analysis below therefore applies to the financial data provided, which appears to represent Disc Medicine.

The statements show a development-stage biotechnology company with no reported revenue in the periods provided. Operating expenses have increased substantially, driven primarily by research and development spending, while recurring net losses and negative operating cash flow remain significant.

  • Strong liquidity remains: Cash and short-term investments totaled approximately $717.7 million at June 30, 2026. This compares with about $730.2 million at March 31, 2026 and $615.9 million at September 30, 2025.
  • Large equity cushion: Total equity was approximately $644.2 million at the end of Q2 2026, versus total liabilities of $90.9 million. The balance sheet remains heavily equity-funded.
  • Very strong short-term liquidity: Total current assets of $732.8 million were more than 24 times total current liabilities of $30.4 million, providing substantial coverage for near-term obligations.
  • Quarterly operating cash burn improved sequentially: Net cash used in operating activities declined from $62.2 million in Q1 2026 to $44.2 million in Q2 2026.
  • Investment income provides support: Interest and investment income was $6.5 million in Q2 2026, partially offsetting the operating loss and reflecting the benefit of the company’s sizable cash and investment portfolio.
  • Cash runway appears considerable but depends on spending: Using Q2 2026 operating cash usage as a rough guide, the company’s cash and short-term investments could cover approximately 16 quarters of operating burn. This estimate excludes changes in research spending, financing, investments and clinical-development costs.
  • Investment activity drives much of the cash-flow volatility: In Q2 2026, investment maturities and sales exceeded purchases by approximately $21.6 million, while the company also generated $32.3 million from financing activities. These inflows helped produce a $9.8 million increase in cash despite negative operating cash flow.
  • Revenue remains absent: Reported revenue was $0 in each income statement supplied. The company therefore has no operating revenue stream to fund research and development.
  • Losses have widened over time: Quarterly net loss increased from $16.2 million in Q3 2022 to $59.5 million in Q2 2026. The latest attributable loss was $60.6 million, or $1.54 per basic and diluted share.
  • Operating expenses have expanded sharply: Quarterly operating expenses rose from $10.5 million in Q3 2022 to $65.1 million in Q2 2026. Research and development expense increased from $7.9 million to $46.9 million over the same comparison, indicating a materially higher cash requirement as development programs advance.

The longer-term balance-sheet trend is mixed. Total assets increased from approximately $106.0 million in Q3 2022 to $735.1 million in Q2 2026, largely because of equity financing and the accumulation of short-term investments. However, retained earnings declined to a deficit of $633.2 million, reflecting the company’s cumulative losses.

Financing has been important to maintaining liquidity. Common equity issuance was particularly significant in 2023 through 2025, including $234.3 million in Q1 2025 and $206.3 million in Q4 2025. While these financings strengthened the balance sheet, the growth in common stock and weighted-average shares also indicates dilution risk for existing shareholders. Long-term debt rose to $59.3 million by Q2 2026, adding leverage that was not present in the earlier periods shown.

Overall, the provided data depicts a well-capitalized but unprofitable biotechnology company. Investors benefit from substantial liquidity and a low near-term liability burden, but the absence of revenue, rising research costs, persistent operating cash burn, cumulative losses and reliance on capital markets remain significant risks. The ticker and company-name mismatch should be resolved before using these figures to evaluate GMTX.

09/03/26 05:58 PM ETAI Generated. May Contain Errors.

Gemini Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gemini Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Gemini Therapeutics' net income appears to be on an upward trend, with a most recent value of -$212.18 million in 2025, rising from -$40.84 million in 2020. The previous period was -$109.36 million in 2024.

Gemini Therapeutics' total operating income in 2025 was -$236.02 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $236.02 million

Over the last 5 years, Gemini Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Gemini Therapeutics' total liabilities were at $67.05 million at the end of 2025, a 26.1% increase from 2024, and a 122.2% increase since 2020.

In the past 5 years, Gemini Therapeutics' cash and equivalents has ranged from $4.50 million in 2020 to $360.38 million in 2023, and is currently $91.15 million as of their latest financial filing in 2025.

Over the last 5 years, Gemini Therapeutics' book value per share changed from -1.41 in 2020 to 19.60 in 2025, a change of -1,492.7%.


Related Companies

Financial statements for NASDAQ:GMTX last updated on 7/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel